Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma
Xiang X, Shetty K, Yu H, Mishra B, Wong L, Zhou X, Satapathy S, Crawford J, Latham P, Han S, Mathew B, Dagher N, Lau L, Cacaj F, Vegesna A, Dasarathy S, He A, Huang H, Amdur R, Mishra L. Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma. Liver International 2025, 45: e70325. PMID: 40919824, PMCID: PMC12416123, DOI: 10.1111/liv.70325.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorCarcinoma, HepatocellularCross-Sectional StudiesFemaleHumansLiver CirrhosisLiver NeoplasmsLogistic ModelsLongitudinal StudiesMaleMiddle AgedProspective StudiesProteomicsReceptor, Transforming Growth Factor-beta Type IIRisk AssessmentRisk FactorsTransforming Growth Factor betaConceptsRisk of hepatocellular carcinomaHepatocellular carcinomaCohort ALogistic regression analysisCohort CLongitudinal follow-up analysisTGF-bHepatocellular carcinoma riskCancer-related deathsProtein signaturesSix-protein panelSerum proteomic profilesLate-stage diagnosisAFP levelsCirrhotic patientsCohort BMulticenter studyLogistic regression analyses of cross-sectional dataClinical factorsMultivariable prediction modelEarly diagnosisMatched subgroupsPatientsCirrhosisFunction biomarkersTu1516: VALIDATION OF SERUM BIOMARKERS THAT INCLUDE TGF-B AND CORRESPONDING IMMUNE STRATIFY HCC RISK IN CIRRHOTIC PATIENTS
Xiang X, Shetty K, Amdur R, Yu H, Wong L, Chambwe N, Satapathy S, Crawford J, Mishra L. Tu1516: VALIDATION OF SERUM BIOMARKERS THAT INCLUDE TGF-B AND CORRESPONDING IMMUNE STRATIFY HCC RISK IN CIRRHOTIC PATIENTS. Gastroenterology 2025, 169: s-1438. DOI: 10.1016/s0016-5085(25)04195-2.Peer-Reviewed Original ResearchCirrhotic patientsTGF-b
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply